SBIR/STTR Research Award
A biodegradable barrier preventing anastomotic leaks after esophagectomy
Award amount
$406,500Program and phase
SBIR · Phase IAward year
2025Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SAFEGUARD SURGICAL LLC
- Proposal award date
- 2025-09-18
- Contract end date
- 2026-08-31
- UEI
- GCANPGXV3X55
- Solicitation number
- PA24-245
- Topic code
- 102
Research abstract
Project Summary/Abstract This SBIR Phase I application will demonstrate feasibility of LeakGuard by: 1) assessing the mechanical and degradation properties of LeakGuard in esophageal-like conditions and 2) demonstrating LeakGuard’s ability to protect from anastomotic leakage after esophageal resection in the porcine model. Esophageal cancer affects over 50,000 Americans each year. The gold-standard treatment is esophageal resection, but up to 22% of patients develop a complication called anastomotic leakage (AL), resulting in high morbidity and mortality. Current treatments, such as stents and endoscopic vacuum therapy, do not prevent AL and still often result in high patient morbidity and mortality, as well as extended time spent in the hospital. Existing preventative solutions, such as omentoplasty, are surgical based and cannot be performed on every patient and have the potential to result in very serious complications. Therefore, an unmet need exists for an effective method to prevent AL that can be used on any patient, reducing the morbidity and mortality of esophagectomy. SafeGuard Surgical has developed LeakGuard, a biodegradable barrier device that is prophylactically placed within the esophageal lumen during esophagectomy. It covers and protects the esophagogastric anastomotic site enabling esophageal healing, while concurrently preventing anastomotic leakage. The biodegradability of LeakGuard allows for it to be administered during the esophagectomy, eliminating the need for a second surgery. To determine the feasibility of the device, the mechanical and degradation proprieties of LeakGuard will be assessed at pH within the esophageal lumen (4.0 and 7.0). The tensile strength, burst pressure, and fluid permeability will be determined. The ability of the LeakGuard to protect from AL in vivo will be evaluated in a pig model. Pigs will undergo an esophagectomy, and a simulated leak will be created and LeakGuard administered. Pigs will be sacrificed at 7 days, 14 days, and 28 days to evaluate healing and the degree of leak protection. Successful completion of this project will validate that LeakGuard can be used to protect from anastomotic leakage post-esophagectomy.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer